Sjögren’s syndrome: studying the disease in mice by Delaleu, Nicolas Hervé et al.
Introduction
Assuming that studying a model organism will provide us 
with relevant information about the organism of our 
primary interest, investigation of nonhuman animals 
represents an important pillar in today’s biomedical 
research. Over the past decades, the most popular experi-
mental model to emerge is the common house mouse, 
irrespective of diﬀ erent living environments, the evolu-
tionary distance and some well-recognized dis crep an cies 
in innate and adaptive immune responses between mice 
and men. Despite such concerns, researchers generally 
accept these limitations in order to circum navigate tech-
no logical and ethical issues related to research conducted 
in humans. Indeed, immunology has embraced the study 
of mice as a model organism and has accumulated 
tremendous insight into the intricacies of the human 
immune system and its involvement in both preventing 
and eﬀ ecting disease.
In the present article, the murine models for Sjögren’s 
syndrome (SS) are presented along the lines of spon-
taneous and extrinsic-factor induced models of SS-like 
disease and are discussed with special focus on disease 
phenotype and alterations induced in association with 
genetic modiﬁ cation and experimental intervention. We 
also highlight common biological themes reported in 
context with both the etiology and the underlying 
pathogenic mechanisms of experimental SS and address 
their potential relevance for SS in humans.
Sjögren’s syndrome: a summary
SS is a chronic autoimmune disease, which mainly aﬀ ects 
the exocrine glands. Nearly all patients complain of a 
persistent feeling of dry mouth (xerostomia) and dry eyes 
(keratoconjunctivitis sicca) [1,2]. Th ese symptoms can be 
conﬁ rmed by multiple objective tests indicating signiﬁ -
cant functional impairment of the salivary and lacrimal 
glands. Histological evaluation of minor salivary glands 
obtained from patients with SS usually shows large and 
persistent focal inﬁ ltrates of mononuclear cells, often 
referred to as lymphocytic foci. Th ese foci consist of 
mainly T cells, fewer B cells and smaller numbers of 
natural killer cells and dendritic cells. Often associated 
with such inﬂ ammation are acinar epithelial cell atrophy, 
progressive ﬁ brosis and the presence of adipocytes in the 
salivary glands. Since approximately 60 to 80% of patients 
with SS produce anti-Ro antibodies and 40 to 60% pro-
duce anti-La autoantibodies [2], SS diagnosis also relies 
on the presence of these two biomarkers [3].
Aﬀ ecting approximately 0.1 to 0.6% of the total 
population, SS is considered a relatively common rheu-
matic disease. In addition, SS is estimated to be 10 times 
more common in women compared with men. SS may 
extend from an autoimmune exocrinopathy to eﬀ ect 
diverse extraglandular manifestations in the musculo-
skeletal, pulmonary, gastrointestinal, hepatobiliary, hemato-
logic, vascular, dermatologic, renal and nervous systems. 
In contrast to systemic lupus erythematosus (SLE), where 
increased mortality has been reported as a consequence 
of the disease, the overall mortality in SS is comparable 
with the rate in the general population [4]. Th e risk of 
developing non-Hodgkin’s lymphoma, however, is reported 
to be increased 16-fold in patients with SS compared 
with a control population [5]. Unfortunately, all therapies 
tested to date have proven ineﬀ ective in reversing the 
course of SS. Regrettably, relatively few studies in the 
ﬁ eld of rheuma tology address SS speciﬁ cally.
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With the possible exceptions of a few autoimmune 
diseases (for example, rheumatic heart disease), the 
etiology of most autoimmune diseases remains a mystery. 
Th e latter is also true for SS, despite multiple attempts to 
identify factors that might trigger the onset of a patho-
genic immune response speciﬁ cally directed against the 
exocrine glands. With a subset of SS patients exhibiting 
strong type 1 and type 2 interferon signatures [6,7], there 
is reason to believe that a viral agent is involved – but 
why some individuals are susceptible and others are not 
most probably resides in the individual’s genetic back-
ground. An activated type 1 interferon system has also 
been des cribed in other autoimmune diseases (for 
example, SLE) [8]. Much is known about the exogenous 
and endo ge nous inducers of type 1 interferons and the 
molecular path ways that may mediate a continuous 
interferon produc tion involving Toll-like receptor-
dependent ampli ﬁ cation and propagation of the immune 
response [9]. Less is known, however, about and the 
functional role of speciﬁ c gene variants in the regulation 
of the type 1 interferon system. Complicating this picture, 
unfortu nately, is the fact that an important share of 
patients with SS suﬀ ers from secondary SS, deﬁ ned as SS 
manifested in individuals diagnosed with other 
autoimmune diseases such as SLE, rheumatoid arthritis 
or scleroderma.
Another confounding factor in SS that has surfaced is 
the increasing recognition that the severity of secretory 
dysfunction does not necessarily correlate with the 
degree of leukocytic inﬁ ltration or the loss of acinar 
tissue. Th is raises the distinct possibility that immune 
process-related alterations within the glandular tissues, 
disturbing saliva production and/or secretion, are 
involved in the impairment of exocrine gland secretion 
observed in patients with SS [10,11].
Th e aim of the present review is to provide the reader 
with an overview and speciﬁ c information about murine 
strains that have been proposed as models of SS. Th e 
review also highlights ﬁ ndings and hypotheses regarding 
the etiology and pathogenesis of SS that arose from 
research conducted in animal models [12,13].
Model organisms: a summary
In principle, due to the common descent of all living 
organi sms, discoveries made in one species might pro-
vide scientists with valuable information about another 
species. For this promise to be fulﬁ lled, researchers 
depend on a critical level of conservation between the 
species studied and the species of primary interest. As 
stated earlier in the manuscript, the mouse is the 
organism of choice for the majority of immunologists 
and has also become an integral element of the bed-to-
bedside drug development strategy. As species, humans 
and mice diverged approximately 70 million years ago; 
and from an immunologist’s point of view of special 
importance, they evolved in two diﬀ erent ecological 
niches. Nevertheless, the major paradigms about the 
working principles of the immune system appear to 
translate particularly well between the two species [14]. 
Th ere is a need, however, for further delineation of 
species-speciﬁ c diﬀ erences in order to increase predicta-
bility of how ﬁ ndings from a murine strain may translate 
to a human population [14].
Direct comparison of the human and mouse genomes 
has conﬁ rmed the close relationship of these two 
mammalian species, as there are only about 300 genes 
that are unique to either humans or mice [15]. Because of 
diﬀ erences in the development and lifespan between 
humans and mice, one may certainly argue that signiﬁ -
cant diﬀ erences exist in the timing of gene expressions, 
but the basic workings of molecular and biological 
pathways have been shown to be similar, if not identical. 
One must remember, however, the aspects of very 
distinct diﬀ erences in innate and adaptive immunity that 
exist between mice and men [14]. Nonetheless, one can 
only be impressed by how relevant information from 
mouse studies is to humans. To researchers, perhaps the 
most compelling feature in the context of research using 
animal models is the mouse lifespan and fertility. In 
addition, most societies grant scientists considerable 
liberties in testing new hypotheses in mice by allowing 
genetic manipulation and the strict control of an animal’s 
living environment. As a conse quence, resources related 
to research in mice became highly accessible – including 
thousands of inbred and genetically modiﬁ ed strains, 
detailed experimental protocols, elaborated research-
related reagents and data bases containing extensive data 
collections [16].
Experimental research and Sjögren’s syndrome
Several aspects either directly related to the nature of SS 
or associated with current technical limitations under-
score the necessity for research involving animal models. 
Prior to the onset of overt SS, physiological and structural 
changes are thought to take place in the exocrine glands, 
but due to the covert nature of the early stages of auto-
immune diseases, studying these events in patients is 
virtually impossible. Similarly, collection of human speci-
mens that represent a time course of the disease is 
diﬃ  cult.
Ideally, a mouse model of SS mimics several clinical, 
histopathological and immunological features of the 
human disease combined with a high incidence of 
disease. In any cohort of SS patients, however, individuals 
are genetically diverse and the exhibited disease proﬁ les 
are heterogeneous. Th ere is thus signiﬁ cant reason to 
develop multiple murine strains, which manifest, to 
diﬀ erent extents, SS-like disease manifestations. Th is is 
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also important as, obviously, each mouse only represents 
one genetic back ground. Unsuccessful clinical trials, 
based on seemingly promising results of treating auto-
immune diseases in mice, might be due to the fact that 
the trial’s design relied too heavily on a single mouse 
model; for example, non obese diabetic (NOD) mice for 
the study of type 1 diabetes (T1D) [17].
Regarding mechanisms underlying the diﬀ erent aspects 
of the pathogenesis of SS, studying genetically altered 
strains allows the testing of more speciﬁ c hypotheses 
with regard to, for example, a speciﬁ c protein, cell type or 
func tional pathway. Nevertheless, the overall functioning 
principles of a system can often not be predicted by 
studying the properties of its isolated parts as its state 
may strongly rely on the interaction of multiple 
components.
Murine models of spontaneous disease
In outbred populations of higher organisms such as 
rodents, cats, dogs and horses, the occurrence of inﬂ am-
matory conditions reminiscent of autoimmune diseases 
in humans is not uncommon. Also comparable with the 
situation in humans is heterogeneity in terms of genetic 
backgrounds, disease activity and clinical manifestations 
displayed under outbred conditions. A potential explana-
tion for this phenomenon might be related to a possible 
null correlation between some autoimmune diseases and 
reproductive success. Hence, model organisms that 
develop a SS-like disease spontaneously might well, as a 
group, represent the assumed multifactorial etiology and 
complex pathogenesis of SS in humans. As mostly inbred 
strains are used for research purposes, the conclusions 
drawn from an experimental study may translate well to a 
sub population of patients while being only partly valid or 
invalid for other groups of patients with SS.
Th e earliest murine models of SS identiﬁ ed were strains 
that develop SS-like disease manifestations spon ta n-
eously. A pertinent fact is that these models mimic in 
part as a group the complex genetics and diverse disease 
phenotypes found in patients with SS. Th e disease 
phenotypes of these strains are discussed below (Tables 1 
and 2).
NZB, NZW and (NZB/NZW)F1 mice
In (NZB/NZW)F1 mice, histopathological manifestations 
of SS coincide with features reminiscent of SLE [18,19]. 
In NZW mice, exocrine gland inﬂ ammation is more 
pronounced in females compared with males, whereas 
this phenomenon is generally less apparent in NZB mice 
[20,21].
Although other SS-related disease manifestations are 
not very pronounced in (NZB/NZW)F1 mice, a more 
recent study demonstrated that an unspeciﬁ c inﬂ am ma-
tory stimulus, evoked by Freund’s incomplete adjuvant, 
can trigger a signiﬁ cant drop in salivary gland function 
already in an early phase of the disease, while this inter-
vention protocol aﬀ ected anti-Ro levels at a latter disease 
stage [22]. Th ought to alter the sizes of T-cell subsets, 
administration of anti-CD25 monoclonal anti bodies 
shortly after birth also exacerbates sialoadenitis and auto-
antibody production in this strain [23]. Lastly, Toll-like 
receptor 3 engagement through polyinosinic:polycytidylic 
acid has been studied in an attempt to recapitulate the 
eﬀ ect of a dsRNA virus infection on the SS-like disease 
manifested in these mice [24]. As a result, inﬂ ammatory 
mediators downstream of Toll-like receptor 3, such as 
type-1 interferon, were transcribed and a concomitant 
transient loss in salivary gland secretory function was 
observed [24].
MRL and MRL/lpr mice
In 1982 the MRL strain, at the time already established as 
a model of SLE, was reported to develop periductal 
lymphoid inﬁ ltrates in the salivary glands [25]. MRL/lpr 
mice diﬀ er from MRL mice with respect to a mutation 
involving the Fas gene [26]; however, negative selection 
in the thymus does not seem to be impaired in either 
strain [27]. In addition, irrespective of the lpr mutation in 
the Fas gene, MRL/lpr mice express a detectable amount 
of apoptosis-related FAS protein on lymphoid cells [28]. 
Nevertheless, defective apoptosis associated with the lpr 
mutation results in increased susceptibility and severity 
of the disease, most probably through acceleration of the 
disease course [26,28].
Immunohistochemical analyses of the organs targeted 
by the inﬂ ammation show the presence of activated 
T cells [29,30], whose importance was further conﬁ rmed 
in T-cell transfer experiments [31]. Inﬂ ammatory lesions 
in the salivary glands of MRL/lpr mice contain B cells 
producing IgA and IgM rheumatoid factor [32] and were, 
in addition, identiﬁ ed to be sites of IFNγ production [30]. 
Of potential concern, despite female predominance and 
the rare occurrence of anti-Ro autoantibodies, the clinical 
hallmarks of SS – hyposalivation and keratoconjunctivitis 
sicca – are absent in this model.
NFS/sld mice
Th e NFS/sld mouse provides a model in which aberrant 
immune responses against α-fodrin are elicited [33]. A 
defect in salivary gland development leads to aberrant 
enzymatic proteolysis of the structural protein fodrin by 
caspase [33]. Indeed, some patients with SS produce 
antibodies speciﬁ c to the 125 kDa subunit of α-fodrin 
[34]. However, the association between antibodies to α-
fodrin and SS does not seem to be as strong as originally 
thought [35]. Th ymectomy performed in NFS/sld mice 
3 days after birth results in development of T-cell domi-
nated inﬁ ltrates in the salivary and lacrimal glands, 
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and  – secondary to the SS-like disease – the NFS/sld 
mice undergoing thymectomy 3 days after birth also tend 
to develop inﬂ ammatory lesions in other organs [36].
IQI/Jic mic e
Th e IQI/Jic strain was developed from the same stock 
that gave rise to the NOD mouse. Selection, however, was 
for mice that exhibited a SS-like disease comparable with 
NOD mice but in the absence of T1D. IQI/Jic mice 
develop focal inﬂ ammation in the salivary and lacrimal 
glands, accompanied by parenchymal destruction [37]. 
Sialoadenitis progresses over time and becomes more 
prominent in females compared with males. IQI/Jic mice 
also develop inﬂ ammatory lesions in several other 
organs, including the lung, pancreas and kidneys [38]. 
Interestingly, kallikrein-13 has recently been suggested to 
play a role in the etiology of the SS-like disease mani-
fested in IQI/Jic mice [39]. Kallikreins, together with 
other proteases, were found to be part of the salivary 
proteome characteristic for patients with SS [40].
Nonobese diabetic mice and related strains
Th e NOD strain descends from a cataract-prone strain of 
outbred Jcl/ICR mice and is today the most extensively 
characterized model of SS and T1D. Although some 
genetic loci related to diabetes (idds loci) contribute to 
the inﬂ ammatory changes in the exocrine glands, it 
seems that diabetes and SS develop independently of 
each other [41-43]. T1D in NOD mice is restricted to the 
expression of the class II major histocompatibility 
Table 1. Spontaneous models of Sjögren’s syndrome
Strain/
 modifi cationa SS-like disease manifestationsb Remarksb Reference
(NZB/NZW)F1  SG and LG infl . SLE-like disease [19]
MRL SG and LG infl . SLE-like disease [29]
 lpr   SG and LG infl .  lpr exacerbates the MRL disease phenotype [30]
NFS/sld None Aberrant proteolysis of α-fodrin [33]
 3d-Tx   SG and LG infl .  Infl ammatory lesions in multiple organs [34]
IQI/Jic  SG and LG infl . Infl ammatory lesions in multiple organs [37]
NOD SG and LG infl .,  SG and LG function T1D, multiple immune system-related alterations [12]
 H2b   Similar to original NOD strain No T1D [42]
C57BL/6  May develop SG infl . at an old age  Widely used recipient strain 
 NOD-Aec1Aec2  SG and LG infl .,  SG and LG function  Increased applicability compared with NOD mice [41]
 Il2–/–  SG and LG infl .,  SG function  Generalized lymphoproliferative disease [91]
 Il2Rα–/–  SG and LG infl .,  SG function  Generalized lymphoproliferative disease [91]
 Foxp3–/–  None  More susceptible to SS-like disease [94]
 Il10 Tg  SG and LG infl .,  SG and LG function   apoptosis in the SG [95]
 Il14α Tg  SG infl .,  SG function  High incidence of CD5+ lymphoma, nephritis [101]
 Baff  Tg  SG and LG infl .,  SG function  MZ B-cell dominated infl ., SLE-like disease [106]
 Tgfβ1–/–   SG and LG infl .,  SG function  Poor viability, mixed infl ammatory cell response [112]
 Tgfβ1 Tg   SG function  Impaired SG architecture, SG tissue fi brosis [113]
 Thbs1–/–  LG infl ., anti-Ro and anti-La  Detailed assessment of the eye component [116]
 Ar–/–  SG infl .  Estrogen-dependent disease [119]
 RbAp48 Tg  SG and LG infl .,  SG function, anti-Ro and anti-La  Assessment of the infl ammatory milieu in the SG [122]
 Id3–/–   SG and LG infl .,  SG function, anti-Ro and anti-La  Exocrine gland dysfunction precedes SG and LG infl . [125]
 Id3–/–;LckCre  SG and LG infl .,  SG function, anti-Ro and anti-La  T-cell lineage specifi c deletion of Id3 [126]
 r1ΔT/r2n  SG and LG infl ., anti-Ro   Tregs, infl ammatory lesions in multiple organs [130]
 IκBαM/M  SG and LG infl ., anti-Ro and anti-La  Defective feedback regulation of NF-κB [133]
C57BL/10 May develop SG infl . at an old age  C57BL/6 and C57BL/10 diverged prior to 1937 
 NOD-Nss1/Idd5  SG infl .  SG function has not been assessed [82]
SJL SG and LG infl ., anti-Ro and anti-La Susceptible to multiple autoimmune diseases [98]
 Il12 Tg   SG and LG infl .,  SG function,  anti-Ro and anti-La  IL-12 exacerbates the SJL disease phenotype [98]
BALB/c None Often used as control strain  
 Act1–/–  SG and LG infl ., anti-Ro and anti-La  MZ B-cell dominated infl ., SLE-like disease [115]
Selection of murine strains in which Sjögren’s syndrome (SS)-like disease manifestations develop spontaneously. , increased; , decreased; Ar, aromatase; 3d-Tz, 
3 days after birth thymectomy; infl ., infl ammation; LG, lacrimal gland; MZ, marginal zone; NOD, nonobese diabetic mice; SG, salivary gland; SLE, systemic lupus 
erythematosus; T1D, type 1 diabetes; Tg, transgenic; Treg, regulatory T cell. 
aSpecifi c modifi cation of the original strain. bFor modifi ed strains, listings refer to relative 
changes compared with the original, not indented, strain listed above.
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Table 2. Alterations in disease phenotype observed in association with genetic modifi cation and experimental 
intervention
Strain/
 modifi cation/
  intervention SS-like phenotypea Remarksa Reference
(NZB/NZW)F1 SG and LG infl . SLE-like disease [19]
  IFA   SG infl .,  SG function, anti-Ro   DC numbers early in the disease process [22]
  Anti-CD25    SG infl ., anti-Ro   ANA [23]
  Poly(I:C)   SG function (transient)  Role of TLR3 engagement [24]
NOD SG and LG infl .,  SG and LG function T1D, multiple immune system-related alterations [12]
 scid  No SG infl .,  SG function  Abnormal salivary gland physiology remains [60]
 Igμnull    SG function   Insulitis but no progression to overt T1D [64]
 ll4–/–   SG function   Absence of anti-M3R IgG1 [77]
 Ifnγ–/–  No SG infl .,  SG function,  LG infl .  Retained LG infl . [78]
 IfnγR–/–  No SG infl .,  SG function,  LG infl .  Retained LG infl . [78]
 Tnfr1-FcIgG3 Tg   SG and LG infl .  Insulitis but no progression to overt T1D [75]
 Ica69–/–   SG and LG infl .  Unchanged incidence rate of T1D  [61]
 Aire–/–   LG infl .,  LG function  Role of OBP1a and central tolerance [63]
 NZW-Ssial3   SG infl ., SG function unchanged  Unchanged insulitis score [55]
 E2f1–/–   SG infl .,  SG function   T1D,  Tregs [58]
  Hsp60   SG infl .,  SG function   Biomarkers in saliva predict treatment success [57]
  Hsp60 amino acids 437 to 460   SG infl .,  SG function   Biomarkers in saliva indicate SG function [57]
  LTβR-Ig  Arrested progression of SG infl .   Changes in cellular composition of SG infl . [48]
  Anti-VCAM1   LG infl .  LG function, SG infl . and SG function not assessed [76]
  Anti-α4-integrin   LG infl .  LG function, SG infl . and SG function not assessed [76]
  Anti-PNAd   LG infl .  LG function, SG infl . and SG function not assessed [76]
  Anti-L-selectin   LG infl .  LG function, SG infl . and SG function not assessed [76]
  Anti-LFA1   LG infl .  LG function, SG infl . and SG function not assessed [76]
  Il10   SG infl .,  SG function   Retrograde gene delivery through SG ducts [96]
  Tnfr1-Ig   SG function   Retrograde gene delivery through SG ducts [74]
NOD-H2b SG and LG infl .,  SG and LG function No T1D [42]
 ll4–/–   SG function   Absence of anti-M3R IgG1 [65]
 C.Stat6–/–    SG function   Absence of anti-M3R IgG1 [66]
NOD-scid No SG infl ., normal SG function Abnormal salivary gland physiology remains [60]
 Ifnγ–/–  No SG and LG infl .,  SG function  Improved salivary gland physiology [78]
 E2f1–/–   No SG infl ., retained  SG function  Eff ect of E2F1 defi ciency on SG development [59]
C57BL/6.NOD-Aec1Aec2  SG and LG infl .  SG and LG function Increased applicability compared with NOD mice [41]
 C3–/–  No SG and LG infl .,  SG function  Assessing the role of C3 [88]
  Il17r:Fc   SG infl .,  SG function  Retrograde gene delivery through SG ducts [81]
C57BL/6 May develop SG infl . at an old age Widely used recipient strain 
  Il17a  SG infl .,  SG function  Retrograde gene delivery through SG ducts [80]
C57BL/6-Il14α Tg  SG infl .,  SG function High incidence of CD5+ lymphoma, nephritis [101]
 Ltα–/–   SG infl .,  SG function  LTα-dependent disease phenotype [104]
C57BL/6-Id3–/– SG and LG infl .,  SG function, anti-Ro and La Exocrine gland dysfunction precedes SG and LG infl . [125]
  Anti-CD20   SG and LG infl .,  SG function   Depletion of B cells [127]
C57BL/6-Baff  Tg SG and LG infl .,  SG function MZ B-cell dominated infl ., SLE-like disease [106]
 Ltβ–/–   SG infl .,  SG function   MZ B-cell dependence of the SS-like disease [107]
 Tnfα–/–   Unchanged  Increased incidence of B-cell lymphoma [110]
BALB/c-Act1–/– SG and LG infl ., anti-Ro and anti-La MZ B-cell dominated infl ., SLE-like disease [115]
 CD40–/–  SG and LG infl . unchanged  Absence of anti-Ro and anti-La [115]
Selection of genetic modifi cations and specifi c intervention, which gave insight into the mechanisms underlying either the etiology or the pathogenesis of Sjögren’s 
syndrome (SS)-like disease in the original strain. , increased; , decreased; AIRE, autoimmune regulator; ANA, antinuclear antibodies; DC, dendritic cells; E2F1, E2F 
transcription factor 1; HSP, heat shock protein; IFA, Freund’s incomplete adjuvant; infl ., infl ammation; LFA, leukocyte function-associated antigen; LG, lacrimal gland; LT, 
lymphotoxin; M3R, muscarinic acetylcholine type-3 receptor; MZ, marginal zone; NOD, nonobese diabetic mice; OBP1a, odorant binding protein 1a; PNAd, peripheral 
node addressin; poly(I:C), polyinosinic:polycytidylic acid; scid, severe combined immunodefi ciency; SG, salivary gland; SLE, systemic lupus erythematosus; STAT, signal 
transducer and activator of transcription; T1D, type 1 diabetes; Tg, transgenic; TLR, Toll-like receptor; Treg, regulatory T cell; VCAM, vascular cell adhesion molecule. 
aFor 
all modifi ed strains and interventions, listings refer to relative changes compared with the original, not indented, strain listed above.
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com plex (MHC) haplotype H2g7 [44]. Whereas 
NOD.B10-H2b mice are resistant to the onset of overt 
T1D, they still exhibit the main disease manifestations of 
SS [42]. Th e exact extent and cellular composition of the 
glandular inﬂ ammation in NOD.B10-H2b mice, however, 
remains to be deﬁ ned.
NOD mice in which the original MHC H2g7 haplotype 
was replaced with an H2q or H2p haplotype were also 
investigated. In summary, while the diﬀ erence in H2 
haplo type did not seem to aﬀ ect the frequency of sialo-
adenitis, the disease severity varied among these strains 
[43]. Interestingly, introduction of the H2q haplotype 
directed the autoimmune response towards the produc-
tion of SLE-associated autoantibodies and a higher inci-
dence of kidney pathology [43].
Autoimmune manifestations in NOD mice represent a 
complex disease involving genetics, sensitivity to exoge-
nous factors and defects in central and peripheral 
tolerance [44]. Th ese factors have also been reported to 
contribute to the susceptibility of the strain to develop 
autoimmune thyroiditis [45], SLE [46], myasthenia gravis 
[47] and autoimmune encephalomyelitis [44] subsequent 
to speciﬁ c intervention.
In NOD mice, focal inﬂ ammation in the submandibular 
salivary glands and the lacrimal glands develops from 
approximately 8 weeks of age onwards. Th e foci appear 
comparable in structure and cellular composition with 
inﬁ ltrates found in human salivary glands (Figure 1) 
[48,49], and gender-related diﬀ erences in the degree of 
exocrine gland inﬂ ammation have also been reported in 
this strain [50]. As in patients with SS, in NOD mice the 
relationship between histopathological changes and 
hyposalivation is not always obvious – which indicates a 
certain autonomy of the autoimmune manifestations of 
SS (Figure 2) [51]. Exocrine gland inﬂ ammation in NOD 
mice appears to precede the onset of hyposalivation by a 
considerable amount of time [52]. Interestingly, transition 
to an overt disease does not necessarily need to be 
associated with a signiﬁ cantly higher degree of glandular 
inﬂ ammation [52], but hyposalivation and reduction in 
lacrimation were rather correlated with the occurrence of 
B-cell response-related gene transcripts in the exocrine 
glands [53,54].
Supporting the notion of a certain independence 
between degree of inﬂ ammation and glandular hypo-
func tion, introduction of an NZW-derived interval of 
chromosome 7 (annotated Ssial3) into NOD mice moder-
ated sialoadenitis without ameliorating salivary gland 
function [55]. Analyses of dozens of inﬂ ammatory media-
tors in serum and saliva obtained from NOD mice, 
furthermore, only revealed a minimal number of bio-
markers corre lating with several SS-related disease mani-
fes tations in an association network [56]. In addition, 
successful prevention of hyposalivation – through 
administration of 60 kDa heat-shock protein and of 60 
kDA heat-shock protein-derived peptide amino acids 437 
to 460 – did not coincide with a corresponding decrease 
in salivary gland inﬂ ammation [57]. In contrast, bio-
marker signatures generated from saliva, indicating 
qualitative changes in salivary gland inﬂ ammation, 
predicted treatment outcome and salivary gland function 
with high accuracy [57]. Several lines of evidence indicate 
that as T1D progresses from early insulitis to overt 
diabetes there is a loss of immune cell subsets, such as 
regulatory T cells (Tregs) and invariant natural killer T 
cells within the islets [17]. Unfortunately, little is still 
known about the role of these cell subsets in the 
progression of SS. Nevertheless, NOD mice deﬁ cient for 
E2F transcription factor 1 – a regulator of T-cell 
proliferation, diﬀ erentiation, and apoptosis – have a 
pronounced decrease in CD4+CD25+ Tregs and seem to be 
highly predisposed not only to T1D but also to SS [58]. In 
order to investigate the eﬀ ects of E2F transcription factor 
1 deﬁ ciency prior to the involvement of the adaptive 
immune system, the SS disease proﬁ le was later assessed 
in NOD-E2f1–/– mice, which, in addition, carried the 
severe combined immunodeﬁ ciency (scid) mutation. 
Interestingly, this strain’s saliva secretion capacity was 
found impaired [59] irrespective of the severe deﬁ ciencies 
in adaptive immunity and the absence of exocrine gland 
inﬂ ammation reminiscent of SS mediated by the scid 
mutation [60].
Another possible connection between SS and T1D in 
NOD mice might involve common autoantigens. Disrup-
tion of the islet-cell autoantigen 69 kDa gene in NOD 
mice, a self-antigen associated with diabetes that is 
expressed not only in the pancreas but also in the 
exocrine glands, reduced SS-related histopathology and 
glandular hypofunction [61]. A study investigating a large 
cohort of patients with SS could not, however, conﬁ rm a 
role or true frequency of islet-cell autoantigen 69 kDa 
autoimmunity in patients with SS [62]. Studying the role 
of autoimmune regulator deﬁ ciency and central tolerance 
in the context of SS in NOD and Balb/c mice identiﬁ ed 
odorant binding protein 1a as a potential autoantigen 
involved in the etiology of autoimmune-mediated 
lacrimal gland pathogenesis [63].
To determine whether B cells contribute to the SS-like 
disease, experiments were carried out in NOD-Igμnull 
mice, which lack mature B cells [64]. Th e results indicate 
that in SS, in contrast to T1D, B cells do not signiﬁ cantly 
participate in the initiation phase of the disease [44,64]. 
However, B-cell activity appears to be critical in the 
transition to an overt disease stage in these mice, since, 
despite the presence of T cells in the salivary glands, 
NOD-Igμnull mice fail to develop hyposalivation [64]. 
Subsequent studies also documented the concomitant 
lack of hyposalivation and anti-muscarinic acetylcholine 
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type-3 receptor (M3R) autoantibodies of the IgG1 isotype 
in IL-4-deﬁ cient and signal transducer and activator of 
transcription 6-deﬁ cient NOD strains [65,66]. In 
connection with possible non-inﬂ ammatory mechanisms 
underlying the onset of hyposalivation, an altered 
aquaporin 5 distri bution – similar to the patterns 
observed in human specimens – has also been described 
in exocrine glands obtained from NOD mice [67,68].
Protection from T1D in NOD mice has been associated 
with a shift from a Th 1 to a Th 2 cytokine expression 
proﬁ le in autoreactive T cells [17]. Results obtained in 
subsequent studies, however, indicated that compart-
ment ali zation into disease-promoting Th 1 and protective 
Th 2 cytokines cannot be applied to the overall patho-
genesis manifested in NOD mice [69]. Th e emergence of 
novel immune-cell subsets such as Tregs and Th 17 cells 
further questions the validity of such models [70,71].
Cytokine expression in the exocrine glands obtained 
from NOD mice has been analyzed [72,73]. In a later 
study, taking advantage of recent technological develop-
ments, more comprehensive sets of inﬂ ammatory 
mediators were analyzed in serum and saliva obtained 
from NOD mice [56]. Furthermore, blocking of either 
lymphotoxin βR or TNFR1 signaling has given insight 
into the implication of these two TNF family members in 
the development of the SS-like disease in NOD mice 
[48,74]. Whereas lymphotoxin βR signaling appears to 
aﬀ ect the degree and cellular composition of salivary 
gland inﬂ ammation [48], inhibition of TNFR1 engage-
ment has been suggested to exacerbate the manifestation 
of hyposalivation [74]. In an earlier study, however, 
transgenic overexpression of TNFR1 inhibited exocrine 
gland inﬂ ammation [75]. Investigation of antibody-
mediated inhibition of lymphocyte migration as a poten-
tial treatment strategy demonstrated that α4β1-integrin, 
leuko cyte selectin and leukocyte function-asso ciated 
Figure 1. Salivary gland histopathology. Focal mononuclear cell infi ltration of the salivary gland characteristic for Sjögren’s syndrome. 
(a) Hematoxylin and eosin stained section of a submandibular gland, a sublingual gland and parts of the parotid salivary gland with a lymph node. 
(b) Magnifi cation of a focal mononuclear cell infi ltrate. The specimen was obtained from a 21-week-old nonobese diabetic mouse. Figure adapted 
from [51].
Figure 2. Assessment of salivary gland secretion capacity. 
Saliva collection and measurement of the salivary fl ow rate in 
an anesthetized nonobese diabetic mouse subsequent to the 
intraperitoneal injection of pilocarpine. Figure reproduced with kind 
permission from Springer Science & Business Media [13], photograph 
by Nicolas Delaleu.
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antigen 1 expression on lymphocytes and that vascular 
cell adhesion molecule 1 expression and peripheral 
node addressin on endothelial cells are required for 
lympho cyte homing to the lacrimal gland of NOD mice 
[76].
Th e functional roles of Th 1 and Th 2 cytokines in the 
pathogenesis of SS have been assessed in some detail by 
comparing a set of gene knockout mice: NOD-Il4–/– [77], 
NOD.B10-H2b-Il4–/– [65], NOD.B10-H2b-C.Stat6–/– [66], 
NOD-Ifnγ–/– and NOD-Ifnγr–/– [78] mice. Il4–/– NOD 
mice and Stat6–/– NOD mice retain salivary secretion 
rates similar to Balb/c mice despite the fact that they 
continued to present with exocrine gland inﬂ ammation 
[65,66]. NOD-Ifnγ–/– mice and NOD-Ifnγr–/– mice were 
found to develop neither sialoadenitis or hyposalivation 
nor to present the signs of delayed salivary gland organo-
genesis present in the salivary gland of the parental NOD 
strain [60,78]. Of note, the mononuclear cell inﬁ ltrates 
within the lacrimal glands persisted in these two latter 
strains [78]. Results regarding the more recently des-
cribed Th 17-cell subset suggest that the Th 17/IL-23 
system is activated in a NOD-derived strain during the 
overt state of the disease [79]. Interestingly, local IL-17A 
expression as a result of adenovirus vector-associated 
Il17a delivery to the salivary gland of SS nonsusceptible 
C57BL/6 mice recapitulated to a large extent the SS-like 
disease phenotype described in the NOD strain [80]. 
Subsequent investigation of IL-17 as a therapeutic target 
at diﬀ erent disease stages showed that gene therapy-
induced inhibition of IL-17, through expression of its 
receptor in the salivary gland, had the capacity to signiﬁ -
cantly reduce several important features of the SS-like 
disease, including salivary gland inﬂ ammation and 
severity of hyposalivation [81].
To investigate the importance of speciﬁ c gene regions 
with regard to SS-like disease manifestations, NOD-
speciﬁ c genetic loci were introduced into either a 
C57BL/6 background [41] or a C57BL/10 background 
[82]. For both strains, gene expression of the salivary 
gland tissues was compared with their respective parental 
strain [54,82,83]. Unfortunately, the C57BL/10-based 
model termed B10.Q-Nss1/Idd5 has not been assessed 
for salivary gland hypofunction [82].
Th e principal aim for the development of the C57BL/6-
based model named C57BL/6.NOD-Aec1Aec2 was 
primarily to circumnavigate three problems associated 
with its parental NOD strain: the known impact of overt 
T1D on the physiological process of saliva and tear 
secretion as well as the possible interference of T1D, 
overt or asymptomatic, with biological readouts obtained 
from the NOD strain; the fact that there is no appropriate 
comparative nondiseased control strain for NOD mice; 
and the presence of a multitude of immune system-
associated defects in the NOD strain [44].
Th e genes within the genetic regions designated Aec1 
(Idd5 on chromosome 1) and Aec2 (Idd3 on chromosome 
3) appear suﬃ  cient for the manifestation of a SS-like 
disease phenotype comparable with the one manifested 
in NOD mice [41]. First steps towards ﬁ ne-mapping of 
Aec2 were undertaken with the purpose of identifying 
candidate genes potentially regulating SS-associated 
autoimmunity [84]. Nevertheless, although considered 
nonsusceptible to the development of a SS-like disease, 
the genomes of C57BL/6J or C57BL/10 might still 
contribute to the congenic strain’s disease phenotype by 
enhancing the primary eﬀ ects introduced by the congenic 
regions [85]. Such phenomena render it more diﬃ  cult to 
discriminate between disease-causing and disease-
promoting gene segments. In addition, the two recipient 
strains may develop spontaneous sialoadenitis as they age 
[82,86]. Th e improved applicability of the C57BL/6.NOD-
Aec1Aec2 strain compared with the original NOD mice, 
however, facilitated the study of proteases in the initiation 
phase of the disease [87], a more distinct delineation of the 
salivary and lacrimal gland transcriptome prior to and 
during the onset of the SS-like disease [53,54], as well as 
assessment of a potential role of complement 3 in SS [88].
Gene knockout and transgenic models
Genetic modiﬁ cations have been shown to trigger 
diﬀ erent aspects of the SS-like disease in murine models. 
Th e fact that silencing or overexpression of a single gene 
can result in a disease proﬁ le reminiscent of SS points to 
pathways downstream of this particular gene. Th ese 
pathways are commonly associated with either regulating 
the immune response, governing developmental pro-
cesses or contributing to exocrine gland homeostasis. A 
discussion of gene knockout and transgenic models of SS 
follows (Tables 1 to 3).
IL-2-defi cient, IL-2Rα-defi cient and forkhead box 
P3-defi cient mice
Th e ﬁ rst indication that IL-2 activities are diminished in 
NOD mice was ﬁ rst reported in 1993 [89] and was later 
found to be associated with Idd3 [90]. Today, IL-2 is 
recognized as a critical factor in promoting diﬀ erentiation 
and activation of Tregs. Concordantly, inhibition of circu-
lat ing IL-2 led to aggravation of diverse autoimmune 
manifestations in NOD mice [45], and both IL-2-deﬁ cient 
and IL-2Rα-deﬁ cient C57BL/6 mice present with 
exocrine gland inﬂ ammation and hyposalivation [91,92]. 
Th e SS-like disease in the two strains develops, however, 
secondary to a generalized lymphoproliferative disease 
character ized by autoimmune hemolytic anemia and 
inﬂ ammatory bowel disease [93]. Nevertheless, data 
collected on IL-2 in a SS-related context indicate that in 
conditions with decreased regulatory cell populations the 
salivary glands are prone to exhibit autoimmune 
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manifestations. Incon sistently, however, mice that carry 
the forkhead box P3 (Foxp3)sf mutant gene and are 
therefore deﬁ cient for Foxp3+-positive Tregs remain free of 
glandular inﬂ amma tion as long as they are not exposed 
to lipopolysaccharide [94]. Nonetheless, cells isolated 
from their lymph nodes had the capacity to induce 
sialoadenitis in immuno compromised, recombination 
activating gene-1-deﬁ cient recipient mice [94].
IL-10 transgenic mice
Overexpression of IL-10 in C57BL/6J mice provokes 
progressive histopathology and hyposalivation suggestive 
of SS [95]. Il10 transfer into NOD mice, however, partially 
suppressed the appearance of SS-like features [96] – 
indicating a dual role of IL-10 in SS, most probably depen-
dent on temporal or site-speciﬁ c expression patterns of 
IL-10.
IL-12 transgenic mice
Th e inﬂ uence of IL-12 is considerably clearer. Both CBA 
[97] and SJL [98] mice transgenic for Il12 exhibit focal 
inﬂ ammation within their exocrine glands, with the latter 
strain showing an additional array of SS-related mani fes-
tations, including hyposalivation and modest increases in 
autoantibody levels upon aging [98]. In this context, it 
should be noted that SJL mice are generally susceptible to 
pathogenic autoimmunity and are also highly prone to 
develop B-cell lymphoma [99]. In an earlier study, 
concurrent intraperitoneal injection of IL-12 and IL-18 
triggered severe atrophy of the salivary and lacrimal glands 
of various strains [100]. Th ese degenerative changes in 
glandular tissues, however, occurred without lymphocytes 
concomitantly inﬁ ltrating the aﬀ ected glands [100].
IL-14α transgenic mice
By promoting expansion and activation of speciﬁ c B-cell 
subsets, Il14α transgenic C57BL/6 mice present with 
hyper gammaglobulinemia by 3 months of age, with exo-
crine gland inﬂ ammation by 6 months of age [101,102]. 
In addition, this strain develops immune-complex-
mediated nephritis, as well as exhibiting a high incidence 
of CD5+ B-cell lymphoma [101]. Strengthening the 
relevance of this model, a recent study demonstrated a 
strong dependence of the SS-like disease manifestations 
on local expression of lympho toxin α, a molecule crucial 
for the maintenance of organized lymphoid micro-
environ ments in target tissues of autoimmune diseases 
[103]. Il14α transgenic mice deﬁ cient for lymphotoxin α 
retained normal saliva secre tion and presented no signs 
of salivary gland inﬂ am mation or secondary lymphoma 
development [104]. Th is strain also no longer presented 
the disproportionally large CD5+ B-cell compartment, 
characteristic for mice overexpressing Il14α [104].
B-cell-activating factor transgenic mice
B-cell-activating factor (BAFF), also known as B-lympho-
cyte stimulator, has emerged as a critical regulator of B-
cell survival and maturation, demonstrating the need for 
an obligate survival signal for both maturing and fully 
diﬀ erentiated B cells [105]. Excess BAFF-mediated 
survival signals are thought to aid autoreactive B cells to 
escape apoptosis, to expand and, subsequently, to exert 
their potentially pathogenic activities [105].
BAFF received considerable attention following 
develop ment of Baﬀ  transgenic strains, of which one was 
shown to develop features reminiscent of SS, including 
lymphoid inﬁ ltrates in the salivary and lacrimal glands 
and hyposalivation [106]. Th e manifestation of the SS-
like disease thereby critically depends on B cells with a 
marginal zone B-cell like phenotype, which are the 
dominant lymphocyte population inﬁ ltrating the salivary 
glands from this strain [107]. Despite the high numbers 
of B cells, anti-Ro antibodies or anti-La antibodies were 
not detected. Strains overexpressing BAFF also develop 
severe autoimmune manifestations traditionally associa-
ted with SLE, including circulating immune complexes, 
anti-DNA antibodies and immunoglobulin deposition in 
the kidneys [108,109]. Disruption of Tnfα in Baﬀ  
transgenic mice furthermore revealed a critical role of 
the anti-tumor activity of TNFα in this strain [110].
Transforming growth factor beta 1 transgenic and 
defi cient mice
Transforming growth factor (TGF) beta1 is a multifunc-
tional molecule that has eﬀ ects on many developmental, 
physio logical and immunological processes. Animals 
Table 3. Extrinsic factor-induced models of Sjögren’s syndrome
Strain Extrinsic factor  SS-like disease manifestations Remarks Reference
BALB/c Ro amino acids 480 to 494 SG infl .,  SG function, anti-Ro and anti-La Low disease penetrance rate [136]
 Ro amino acids 274 to 290 SG infl .,  SG function, anti-Ro and anti-La Low disease penetrance rate [136]
C57BL/6-Rag1–/– Six peptides from M3R SG and LG infl .,  SG function Splenocytes from vaccinated M3r–/– mice [140]
PL/J CAII SG infl . Infl ammatory lesions in multiple organs [142]
C57BL/6-gld//gld MCMV SG infl ., anti-Ro and anti-La Incomplete clearance of the MCMV [144]
Selection of murine strains in which Sjögren’s syndrome (SS)-like disease manifestations develop after the administration of specifi c extrinsic factors. , increased; 
, decreased; CAII, carbonic anhydrase II; infl ., infl ammation; LG, lacrimal gland; M3R, muscarinic acetylcholine type-3 receptor; MCMV, murine cytomegalovirus; SG, 
salivary gland.
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carry ing a mutated Tgfβ1 allele present a syndrome 
marked by mixed inﬂ ammatory cell responses and tissue 
necrosis, in many cases leading to organ failure and death 
[111]. In surviving mice, the syndrome includes inﬂ am-
mation of the exocrine glands in a large share of the 
animals that can, however, be prevented by systemic 
injections of synthetic ﬁ bronectin peptides [112]. Mice 
overexpressing TGFβ1 in the secretory cells of both the 
mammary and salivary glands exhibit impaired salivary 
gland architecture concomitant with salivary gland 
hypofunction [113]. It is important to note that altered 
TGFβ1 expression in mice results in poor viability and 
surviving mice suﬀ er from hyposalivation in association 
with inﬂ ammation, acinar cell atrophy and ﬁ brosis in the 
salivary glands [111-113].
Adaptor molecule Act-1-defi cient mice
As a negative regulator of BAFF and CD40, the adaptor 
molecule Act 1 (Act1) crucially modulates the survival of 
all B cells [114]. In Act1-deﬁ cient mice, similar to mice 
transgenic for BAFF, marginal-zone-like B cells dominate 
the inﬂ ammation in the exocrine gland that develops 
around 6 months of age [115]. At 8 months of age, levels 
of salivary secretion appear to be slightly diminished, 
while indications for dry eyes – such as scratching and 
skin lesions around the eyes – were observed during the 
breeding process as early as 3 weeks postpartum [115]. 
Another shared trait between the Act1-deﬁ cient strain 
and Baﬀ  transgenic mice is the production of SLE-
associated anti-DNA autoantibodies and the mani-
festation of glomerulonephritis [115]. In contrast with 
Baﬀ  transgenic mice [106], however, deﬁ ciency in Act1 
causes the production of autoantibodies speciﬁ c for Ro 
and La [115]. Further investigation of this phenomenon 
revealed that, compared with the other autoantibody 
speciﬁ cities found in these mice, the production of anti-
Ro autoantibodies and anti-La autoantibodies critically 
depends on functional CD40. As Act1 was more recently 
also identiﬁ ed as a critical signaling component of the 
IL-17 signaling pathway, this aspect needs to be 
addressed in further studies [114].
Thrombospondin-1-defi cient mice
A recent study showed that silencing the thrombospondin 
1 gene (Th bs1) in C57BL/6 mice causes the development 
of a severe and remarkably complete SS-like disease with 
respect to the involvement of the eye [116]. Increased 
apoptosis in the lacrimal glands accompanies their 
progressive deterioration and, in addition, anti-Ro auto-
antibodies and anti-La autoantibodies were detected in 
this strain [116]. Some THBS1-deﬁ cient mice also 
displayed external signs of dry eyes, although the tear 
volume secreted upon stimulation did not diﬀ er between 
the genetically modiﬁ ed mice and the wild-type strain 
[116]. Although a few parameters of lacrimal gland func-
tion signiﬁ cantly decreased before the signiﬁ cant inﬂ ux 
of inﬂ ammatory cells into the glands, the authors argue 
for a critical involvement of the immune system, in par-
ticu lar the Th 17 system, in the observed pathology [116].
THBS1 is capable of activating latent TGFβ and, as 
alluded to previously, dysregulation of the TGFβ system 
aﬀ ects the immune system as well as multiple develop-
mental processes. Although less devastating compared 
with direct deletion of Tgfβ1, THBS1-deﬁ cient mice 
exhibit a similar inﬂ ammatory condition and display 
histo logical abnormalities described for TGFβ-deﬁ cient 
mice [117]. Being a multidomain matrix glycoprotein 
capable of interacting with multiple cell adhesion 
molecules and proteases involved in angiogenesis, it is 
not surprising that THBS1 plays important roles in the 
development of diverse tissues [118]. Taking into account 
these properties of THBS1, investigating immune 
system-unrelated alterations in the exocrine tissues of 
Th bs1-deﬁ cient mice would further clarify the etiology of 
the disease they manifest.
Aromatase-defi cient mice
Th e high female predominance and the late onset of SS in 
humans suggest a possible role of estrogen in the etiology 
of SS. Whereas neither estrogen receptor-alpha-deﬁ cient 
nor estrogen receptor-beta-deﬁ cient strains exhibit SS-like 
disease manifestations, another model for estrogen 
deﬁ ciency – the aromatase knockout mouse – develops a 
lympho proliferative condition that in some aspects 
resembles the histopathological manifestation of SS in the 
salivary glands [119]. In parallel with sialoadenitis, B-cell-
dominated inﬂ ammation of the kidneys and enlargement 
of the spleen were also reported for this strain [119].
Retinoblastoma-associated protein 48 transgenic mice
Estrogen deﬁ ciency caused by ovariectomy was shown to 
increase the number of epithelial cells undergoing apop-
tosis in the salivary glands as well as to have an eﬀ ect on 
the cleavage of structural proteins [120]. Th e observation 
that retinoblastoma-associated protein 48 (RbAp48) contri-
butes to the observed estrogen-dependent modulation of 
apoptosis exclusively in the salivary glands gave reason to 
investigate its role in a strain overexpressing RbAp48 
under the control of a salivary gland speciﬁ c promoter 
[121,122]. From 20 weeks of age onwards, RbAp48 
transgenic mice exhibit inﬂ ammatory lesions in the 
salivary and lacrimal glands, which comprise mostly T 
cells and fewer B cells. At 30 weeks of age, salivary gland 
function was shown to be impaired in the transgenic 
mice compared with the wild-type strain. Increased 
levels of anti-Ro autoantibodies and anti-La auto anti-
bodies complemented the SS-like phenotype observed in 
RbAp48 transgenic mice [122]. Th e investigators also 
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collected considerable data that suggest a dominant role 
of resident cells in the initiation and perpetuation of the 
disease, especially by contributing to MHC-II-dependent 
antigen presentation and modulation of the cytokine 
milieu [122].
Id3-defi cient mice
Inhibitors of DNA binding (ID) proteins are inhibitors of 
basic helix–loop–helix transcription factors and act as 
regulators of proliferation and diﬀ erentiation of immune 
and non-immune cells [123]. Th e immune system of 
C57BL/6-Id3–/– mice is characterized by alteration in 
humoral immune reactions, marginal zone B-cell 
develop ment, B-cell precursor survival and both MHC-I-
restricted and MHC-II-restricted positive and negative 
selection [124]. In these mice, T-cell-dominated focal 
inﬂ ammation develops between 6 and 12 months of age, 
coinciding with anti-Ro autoantibody and anti-La auto-
antibody production. Th e same strain, however, shows 
severe exocrine gland dysfunction as early as between 6 
and 18 weeks of age – long before the appearance of focal 
lymphocytic foci in their exocrine glands [125]. 
Nevertheless, the notion that disruption of certain genes 
triggers distinct pathological changes, almost exclusively 
limited to the salivary and lacrimal glands, may 
encourage further investigation of possible inter relation-
ships between organ and lymphocyte development and 
the etiology of autoimmune diseases. In this context, 
investigation of a T-cell-targeted conditional Id3 knock-
out strain revealed the strong dependence of the original 
C57BL/6-Id3–/– strain’s disease proﬁ le on ID3-deﬁ cient 
T  cells in particular [126]. Interestingly, depletion of B 
cells ameliorated the SS-like disease in this strain [127]. 
Th e role of ID3 in SS is now under investigation in 
humans, but to date there are no SNPs in Id3 associated 
with SS in humans [128].
Phosphoinositide 3 kinase class-IA-defi cient mice
Th ere is an abundance of information that implicates 
phosphoinositide 3 kinase class IA in the development 
and onset of autoimmune diseases [129]. Mice with a T-
cell-speciﬁ c loss of phosphoinositide 3 kinase class IA 
(r1ΔT/r2n) develop an inﬂ ammatory condition reminis-
cent of SS in the lacrimal glands that parallels the 
occurrence of inﬂ ammatory lesions in the lungs, liver and 
intestines in these mice [130]. While exocrine gland 
function was not assessed in detail, the authors report a 
decrease in Tregs in the periphery and increased anti-Ro 
antibodies and anti-La antibodies as a result of this 
speciﬁ c genetic modiﬁ cation.
Knockin mice with mutated κB enhancers in the IκBα promoter
Aberrant regulation of nuclear factor of kappa light 
polypeptide gene enhancer in B cells (NF-κB) has been 
associated with inﬂ ammatory and autoimmune diseases 
since its crucial role in both innate and adaptive immunity 
was reported [131]. Among other autoimmune condi-
tions, certain poly morphisms in the promoter of NF-κB 
inhibitor nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor alpha (IκBα) might 
contribute to an individual’s susceptibility to develop SS 
[132]. Removal of the feedback regulation of NF-κB by 
introducing κB enhancers in the IκBα (IκBαM/M) promoter 
of C57BL/6 mice altered the expression of NF-κB-
associated genes such as Il17 and genes involved in T-cell 
development [133]. Subsequently, inﬂ ammation in the 
exocrine glands, concomitant with production of anti-Ro 
autoantibodies, anti-La autoantibodies and anti-DNA 
autoantibodies, were observed in these mice without, 
however, assessing exocrine gland function [133]. Th e 
overall phenotype of this strain, in addition, is charac-
terized by involvement of various other organs, shortened 
lifespan and hypersensitivity to septic shock [133].
Extrinsic factor-induced models
For the strains described earlier in this manuscript, the 
etiology of SS-like disease manifestations is assumed to 
be, to a large extent, associated with the mouse’s speciﬁ c 
genetic background. Th e experimental models presented 
below are strains in which the development of a SS-like 
pathology requires administration of extrinsic factors, 
such as proteins and peptides or viruses (Table 3). Such 
protocols are based on the concept that injecting speciﬁ c 
components emulsiﬁ ed in an adjuvant can break 
immuno logical tolerance to certain organ-speciﬁ c or 
organ-unspeciﬁ c structures. Th is event might subse-
quently be followed by an immune-system-initiated 
pathogenesis. Th e components injected in such studies 
are mostly selected on the basis on their suspected role in 
the disease of interest. As alluded to previously, unfor-
tunately, the current knowledge about disease-relevant 
autoantigens in SS is limited – which might be one 
reason why induced models are not of equal importance 
in SS as, for example, in studying multiple sclerosis [134] 
or rheumatoid arthritis [135].
Ro peptides
Repeated intraperitoneal injection of the Ro peptides – 
Ro amino acids 480 to 494 or Ro amino acids 274 to 290 – 
emulsiﬁ ed in complete Freund’s adjuvant and later in 
Freund’s incomplete adjuvant has been shown to 
recapitulate some manifestations of SS in Balb/c mice 
[136]. Th ese mice present with hyposalivation, SS-like 
histopathology and production of anti-Ro antibodies and 
anti-La antibodies by 38 weeks of age [136]. Unfor tu-
nately, the actual penetrance rate of the SS-like disease 
proved to be low, thereby limiting the potential value of 
the model [136]. Oral feeding of Ro or Ro peptides 
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abolished the susceptibility of Balb/c mice to SS-like 
disease induction through the experimental procedure 
described above [137]. While these studies were designed 
to determine whether Ro, as an autoantigen, is impor tant 
in the etiology of SS, there is still a question as to how Ro 
might actually be presented to the immune system [138]. 
In light of a recent study indicating that Ro52 is a negative 
regulator of proinﬂ ammatory cytokine production [139], 
if and how these newly described pro perties of Ro52 
contribute to SS remain to be investigated.
Muscarinic acetylcholine type-3 receptor peptides
As alluded to above, antibodies targeting the M3R may 
directly mediate the inhibition of exocrine gland secre-
tion by inhibiting neuronal innervation of acinar cells. A 
recent study assessed the question further by vaccinating 
C57BL/6-M3r–/– mice with a six-valent mixture of free-
form extracellular peptides of M3R [140]. Indeed, the 
inoculation of splenocytes or CD3+ T cells into immuno-
deﬁ cient C57BL/6-Rag1–/– mice triggered the develop-
ment of marked mononuclear cell inﬂ ammation in the 
exocrine glands accompanied by salivary gland hypo-
function [140]. Th is study further supports the notion of 
a direct pathogenic role of anti-M3R immunity in SS [10].
Carbonic anhydrase
A subset of patients with autoimmune diseases, including 
patients with SS, produces autoantibodies against carbonic 
anhydrase II [141]. Studies carried out in mice revealed 
that experimental sialoadenitis can be induced through 
carbonic anhydrase II immunization of PL/J mice [142] 
as well as congenic strains of PL/J mice carrying the a H2s 
or a H2u haplotype [142]. Additional studies are required, 
however, to be able to estimate in more detail the 
resemblance of the disease manifested in this model with 
SS in humans.
Murine cytomegalovirus
Intraperitoneal injection of murine cytomegalovirus has 
been documented to lead to sialoadenitis and production 
of anti-Ro autoantibodies and anti-La autoantibodies in 
genetically modiﬁ ed C57BL/6 mice [143]. Th e modiﬁ  ca-
tions, aﬀ ecting either FAS-mediated or TNFR1-mediated 
apoptosis, resulted in an incomplete clearance of murine 
cytomegalovirus, suggesting that any defect in this 
response may evoke chronic inﬂ ammation that resembles 
the histopathologlogical changes characteristic for SS 
[143]. In a subsequent study, C57BL/6-gld/gld mice, which 
are Fas ligand deﬁ cient, were treated with an adenoviral 
viral vector inducing the overexpression of Fas ligand 
[144]. In light of high levels of Fas ligand expression 
following injection of the vector, fewer than 5% of ductal 
and acinar cells proved to be apoptotic. Nevertheless, the 
intervention caused signiﬁ cant reductions in the number 
of inﬂ ammatory foci and the degree of tissue destruction 
in the salivary glands [144].
Conclusions
SS is a complex autoimmune exocrinopathy that over 
time often progresses to a systemic disease. Interpatient 
heterogeneity is a major component of this rheumatic 
disease, as evidenced by the array of symptoms exhibited 
by patients at clinic visits. Although numerous mouse 
strains are being proposed as models of SS, it is not 
surprising that no single model can perfectly match the 
full spectrum of SS observed in a human population. In 
the present review, we describe how the genetic 
background of these models and intervention protocols 
modulated the disease proﬁ le they project. Individual 
genetic alterations and their contribution to diﬀ erent 
disease stages and speciﬁ c manifestations of SS might 
one day be assembled to depict a more complete and 
integrated picture of SS.
Today researchers are presented with several alter na-
tives regarding spontaneous and genetically modiﬁ ed 
models of SS: yet, because of the complexity of SS, 
additional models will undoubtedly be required. Unfor-
tunately, the limited knowledge about SS disease-relevant 
autoantigens and SS-related genetic risk factors 
continues to impede the development of extrinsic factor-
induced models of SS.
In recent years there has been a positive trend towards 
testing hypotheses through genetic modiﬁ cation or 
intervention protocols in established models of SS. 
Results from these studies have often yielded insight into 
mechanisms potentially associated with the pathology of 
SS. Th e identiﬁ cation of B-cell-dependent mechanisms of 
pathogenesis in murine models, coupled with investi-
gation of treatment strategies such as anti-CD20 anti-
bodies targeting B cells in patients with SS, exemplify 
such translational advances. Nevertheless, it has become 
ever more challenging to keep pace with the develop-
ments in immunology and to be able to, at least partly, 
assess the importance of newly discovered components 
such as novel immune-cell subsets or regulatory path-
ways in a SS-related context. An assortment of well-
characterized murine strains is needed in order to 
investigate possible roles of these components at the 
diﬀ erent stages of SS. In the past few years, there has also 
been an increase in the number of studies assessing the 
role of possibly relevant and immune system-unrelated 
processes in the etiology of SS. Again depending greatly 
on animal models, such research initiatives are expected 
to yield an increasing number of relevant biomarkers, 
which may specify an individual’s risk of developing SS or 
may indicate an early stage of disease.
It also has become clear that murine strains, in some 
cases, represent a stereotypic or incomplete picture of 
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their human disease counterpart. To counteract this 
issue, in-depth characterization of individual models as 
well as reliance on results obtained in multiple models is, 
however, anticipated to increase the success rate of 
translational studies.
In conclusion, many advances in the ﬁ eld of SS have 
their basis founded in discoveries initially made in animal 
models. Improved collaboration among scientists that 
develop animal models, researchers that apply animal 
models to investigate SS-related aims and clinicians that 
have access to well-deﬁ ned SS patient cohorts should 
accelerate the discovery of novel disease mechanisms 
that lead to development of eﬀ ective treatment regimens.
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